Many Questions, Few Answers On New NSF Science Centers

WASHINGTON—A National Science Foundation proposal to spend $50 million next year on up to 20 science and technology centers, touted by Director Erich Bloch as a partial solution to the country's economic problems, is actually an untested idea that has raised numerous questions among the scientific community. NSF is supporting three separate efforts, one in-house, to help it decide how to create, operate and evaluate such basic research facilities. Congress has already heard Xestimony from

Written byJeffrey Mervis
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

NSF is supporting three separate efforts, one in-house, to help it decide how to create, operate and evaluate such basic research facilities. Congress has already heard Xestimony from representatives of several major scientific organizations on the need to move slowly and carefully.

Chief among their concerns are:

"I expect the centers to focus on areas that are important to the U.S. economy," said Richard Nicholson, assistant director for Mathematical and Physical Sciences and coordinator of the Foundation's five-year plan for the centers. "It's not un-American to worry about the contribution of science to improving the country's economic indicators.

"If Erich Bloch had asked for more money to do fundamental research on quarks, we'd be looking at a smaller budget instead of the 18 percent increase that has been proposed by this administration. We're not promising to eliminate the federal deficit, but training and the production of knowledge are keys to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies